Patrik Tolf steps down as CFO of the Vitrolife Group - Helena Wennerström appointed acting CFO

Vitrolife AB (publ) announces today that Patrik Tolf will be stepping down as Chief Financial Officer due to personal reasons. Helena Wennerström will assume the role of acting CFO. Helena has extensive experience in finance and business management, including having served as CFO at ViaCon Group AB and EVP & CFO at Bulten AB.

"We are very pleased that Helena Wennerström is taking on the role of acting CFO. She will bring deep competence and a wealth of experience to the Vitrolife Group. I would like to take this opportunity to sincerely thank Patrik for his contributions to the company over the past three years and wish him every success in the future", Bronwyn Brophy O'Connor, CEO of Vitrolife Group.

Helena Wennerström will immediately assume the role of acting CFO and Patrik will be here to support her during a transition period. The recruitment of a permanent CFO is being initiated.

Gothenburg, December 3, 2024
VITROLIFE AB (publ)
Bronwyn Brophy O’Connor, CEO

The information was submitted for publication, through the agency of the contact persons set out above, at 03-12-2024 10:30 CET.

Contact:
Bronwyn Brophy O'Connor, CEO, bbrophy@vitrolife.com
Amelie Wilson, Investor Relations, awilson@vitrolife.com

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife Group is a global provider of medical devices and genetic testing solutions. Our vision is to enable people to fulfil the dream of having a healthy baby. Our mission is to be the leading global partner in reproductive health, striving for better treatment outcomes for patients. With 1,100 employees worldwide and headquarters in Gothenburg, Sweden, our products and services are available in over 125 countries through our direct presence and a network of distributors. Vitrolife AB (publ) is listed on Nasdaq Stockholm.